{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-022362","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.051529+00:00","generated_at":"2026-05-31T22:33:55.627333+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024","bullets":["FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.","Meeting scheduled for August 2, 2024; background materials released two business days prior.","PDUFA action date for arimoclomol is September 21, 2024.","Arimoclomol is an orally delivered, first-in-class treatment for NPC, a rare genetic disease.","Zevra CEO highlights opportunity for NPC community to share treatment needs with the advisory committee."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-022362","json":"https://secwatch.observer/filing/0001437749-24-022362.json","markdown":"https://secwatch.observer/filing/0001437749-24-022362.md","text":"https://secwatch.observer/filing/0001437749-24-022362.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924022362/0001437749-24-022362-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774924022362/zvra20240614_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:33:55.627333+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}